活動性関節リウマチ患者におけるBaricitinib 2mg/日治療の長期有効性: 2つの24週 Phase III 無作為化対照試験と1つの長期延長試験の事後解析

Wells AF, et al. Rheumatol Ther. 2021. Epub ahead of print. DOI: 10.1007/s40744-021-00317-9.

Analysis by Wells, et al. demonstrates long-term efficacy and tolerability of baricitinib 2 mg daily for up to 120 weeks in patients with rheumatoid arthritis.Using data from two completed phase III studies, RA-BEAM (csDMARD-IR patients) and RA-BEACON (TNFi-IR patients), and one ongoing long-term extension study (RA-BEYOND), results demonstrated that the long-term maintenance of clinically relevant treatment goals, including LDA, remission and normative physical function, is achievable with baricitinib 2 mg.In addition, low discontinuation rates through 120 weeks of treatment highlight that baricitinib 2 mg was well-tolerated through this treatment period.

LinkedIn